{"id":71617,"date":"2026-03-09T12:15:08","date_gmt":"2026-03-09T12:15:08","guid":{"rendered":"https:\/\/indogenmed.org\/?post_type=product&#038;p=71617"},"modified":"2026-08-27T20:00:52","modified_gmt":"2026-08-27T20:00:52","slug":"pazolong-200mg-tablet","status":"publish","type":"product","link":"https:\/\/indogenmed.org\/ja\/product\/pazolong-200mg-tablet\/","title":{"rendered":"\u30d1\u30be\u30ed\u30f3\u30b0200mg\u9320"},"content":{"rendered":"<div id=\"model-response-message-contentr_5eb7c9682234edda\" dir=\"ltr\" aria-busy=\"false\" aria-live=\"polite\">\n<h2 data-path-to-node=\"3\">Comprehensive Patient &#038; Clinician Guide to Pazolong 200mg Tablet (Pazopanib Hydrochloride)<\/h2>\n<div>Pazolong 200mg Tablet is an advanced targeted anti-cancer medication classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor. Manufactured by MSN Laboratories, each film-coated tablet contains 200 mg of pazopanib (as pazopanib hydrochloride).<\/div>\n<div>Pazolong 200mg is prescribed under specialist oncologist supervision to treat adult patients diagnosed with advanced renal cell carcinoma (kidney cancer) and specific subtypes of advanced soft tissue sarcoma.<\/div>\n<div><\/div>\n<div>Unlike conventional chemotherapy that indiscriminately damages rapidly dividing cells throughout the body, Pazolong is designed for precision anti-angiogenesis\u2014inhibiting the growth of new blood vessels that solid tumors require to receive oxygen and essential nutrients.<\/div>\n<h2 data-path-to-node=\"7\">Molecular Pharmacology &#038; Mechanism of Action<\/h2>\n<div>Solid tumors depend on an uninterrupted blood supply to expand beyond a few millimeters. When tumor cells experience low oxygen (hypoxia), they secrete signaling proteins that bind to receptors on nearby endothelial cells, initiating new blood vessel formation\u2014a process termed tumor angiogenesis.<\/div>\n<div><\/div>\n<div>Pazopanib enters cells and binds to the intracellular adenosine triphosphate (ATP)-binding pocket of multiple receptor tyrosine kinases:<\/div>\n<ul data-path-to-node=\"12\">\n<li>\n<div>Vascular Endothelial Growth Factor Receptors (VEGFR-1, VEGFR-2, VEGFR-3): Inhibits endothelial cell proliferation, migration, and vascular permeability.<\/div>\n<\/li>\n<li>\n<div>Platelet-Derived Growth Factor Receptors (PDGFR-\u03b1, PDGFR-\u03b2): Blocks pericyte recruitment and vascular mural cell stabilization.<\/div>\n<\/li>\n<li>\n<div>Stem Cell Factor Receptor (c-KIT): Inhibits signaling pathways essential for cellular survival and growth.<\/div>\n<\/li>\n<li>\n<div>Fibroblast Growth Factor Receptors (FGFR-1, FGFR-3): Suppresses secondary angiogenic pathways.<\/div>\n<\/li>\n<\/ul>\n<div>By simultaneously blocking these receptors, Pazolong starves the tumor microenvironment of oxygen and nutrients, halting tumor growth and inducing cell death (apoptosis).<\/div>\n<h2 data-path-to-node=\"15\">Approved Therapeutic Indications<\/h2>\n<div>Pazolong 200mg Tablet is indicated for adult patients in specific clinical oncological settings:<\/div>\n<ul data-path-to-node=\"17\">\n<li>\n<div>Advanced or Metastatic Renal Cell Carcinoma (aRCC): Prescribed as a first-line treatment for advanced kidney cancer or as a second-line option following disease progression after prior cytokine therapy.<\/div>\n<\/li>\n<li>\n<div>Advanced Soft Tissue Sarcoma (aSTS): Indicated for adult patients with advanced soft tissue sarcoma who have previously received chemotherapy (e.g., anthracyclines) or whose disease has progressed.<\/div>\n<ul data-path-to-node=\"17,1,1\">\n<li>\n<div>Clinical Limitation: Safety and efficacy have not been established in gastrointestinal stromal tumors (GIST) or liposarcomas (adipocytic sarcomas).<\/div>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h2 data-path-to-node=\"19\">Standard Dosage and Administration Guidelines<\/h2>\n<div>Pazolong 200mg must be administered strictly according to your oncologist\u2019s prescription.<\/div>\n<h3 data-path-to-node=\"21\">Standard Dosage Protocols<\/h3>\n<ul data-path-to-node=\"22\">\n<li>\n<div>Standard Daily Dose: The standard adult starting dose is 800 mg taken orally once daily (taken as four 200mg tablets together at the same time each day).<\/div>\n<\/li>\n<li>\n<div>Role of the 200mg Strength: The 200mg tablet allows for precise dose adjustments:<\/div>\n<ul data-path-to-node=\"22,1,1\">\n<li>\n<div>First Step-Down: Reduction to 600 mg daily (three 200mg tablets).<\/div>\n<\/li>\n<li>\n<div>Second Step-Down: Reduction to 400 mg daily (two 200mg tablets).<\/div>\n<\/li>\n<li>\n<div>Minimum Therapeutic Dose: Reduction to 200 mg daily (one 200mg tablet) for patients experiencing specific toxicities or with moderate baseline liver impairment.<\/div>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h3 data-path-to-node=\"23\">The Strict Empty-Stomach Requirement<\/h3>\n<div>Pazolong must be taken on an empty stomach:<\/div>\n<ul data-path-to-node=\"26\">\n<li>\n<div>Take your dose at least 1 hour before a meal, OR<\/div>\n<\/li>\n<li>\n<div>Wait at least 2 hours after a meal before taking your tablets.<\/div>\n<\/li>\n<\/ul>\n<div>Why is this strict window essential? Taking pazopanib with food\u2014especially high-fat or high-calorie meals\u2014can double or triple the amount of drug absorbed into your bloodstream.<\/div>\n<div><\/div>\n<div>This unpredictable surge significantly raises the risk of severe liver damage, high blood pressure, and heart rhythm complications.<\/div>\n<h3 data-path-to-node=\"28\">Administration Checkpoints<\/h3>\n<ul data-path-to-node=\"29\">\n<li>\n<div>Swallow Whole: Swallow tablets whole with a full glass of water. Do not chew, crush, split, or dissolve the tablets, as this breaks the film coating and causes dangerous spikes in absorption.<\/div>\n<\/li>\n<li>\n<div>Missed Dose Instructions: If you miss a dose by more than 12 hours, take it as soon as you remember. If your next dose is due in less than 12 hours, skip the missed dose and resume your regular schedule the following day. Never take a double dose.<\/div>\n<\/li>\n<\/ul>\n<h2 data-path-to-node=\"31\">Potential Side Effects &#038; Clinical Management Strategies<\/h2>\n<div>Because Pazolong targets vascular signaling throughout the body, side effects across several organ systems may occur.<\/div>\n<h3 data-path-to-node=\"33\">Common Adverse Reactions<\/h3>\n<table data-path-to-node=\"34\">\n<thead>\n<tr>\n<td>Organ System<\/td>\n<td>Common Symptoms<\/td>\n<td>Clinical Management<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u80c3\u8178<\/td>\n<td>\u4e0b\u75e2\u3001\u5410\u304d\u6c17\u3001\u5614\u5410\u3001\u98df\u6b32\u6e1b\u9000\u3001\u5473\u899a\u5909\u5316\uff08\u30b8\u30b0\u30bb\u30a6\u30b7\u30a2\uff09\u3002<\/td>\n<td>\u4f53\u6db2\u3068\u96fb\u89e3\u8cea\u3092\u5341\u5206\u306b\u6442\u53d6\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u5c11\u91cf\u3067\u983b\u7e41\u306b\u98df\u4e8b\u3092\u6442\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u4e0b\u75e2\u6b62\u3081\u85ac\uff08\u4f8b\uff1a\u30ed\u30da\u30e9\u30df\u30c9\uff09\u306f\u51e6\u65b9\u3055\u308c\u308b\u3053\u3068\u304c\u3042\u308a\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr>\n<td>\u76ae\u819a<\/td>\n<td>\u9aea\u8272\u306e\u5909\u5316\uff08\u8131\u8272\/\u767d\u5316\uff09\u3001\u76ae\u819a\u306e\u8584\u304f\u306a\u308b\u3001\u4e7e\u71e5\u3057\u305f\u76ae\u819a\u3001\u76ae\u819a\u767a\u75b9\u3001\u624b\u8db3\u76ae\u819a\u53cd\u5fdc\u3002<\/td>\n<td>\u9999\u6599\u306e\u306a\u3044\u512a\u3057\u3044\u4fdd\u6e7f\u5264\u3092\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u67d4\u3089\u304b\u3044\u5c65\u7269\u3092\u7740\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u8131\u8272\u306f\u4e00\u6642\u7684\u3067\u3001\u6cbb\u7642\u7d42\u4e86\u5f8c\u306b\u901a\u5e38\u306f\u9006\u8ee2\u3057\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr>\n<td>\u5fc3\u8840\u7ba1<\/td>\n<td>\u9ad8\u8840\u5727\u3002<\/td>\n<td>\u81ea\u5b85\u3067\u8840\u5727\u3092\u9031\u306b1\u56de\u6e2c\u5b9a\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u6a19\u6e96\u7684\u306a\u7d4c\u53e3\u964d\u5727\u85ac\u306f\u901a\u5e38\u3001\u4f75\u7528\u3055\u308c\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr>\n<td>\u5168\u8eab<\/td>\n<td>\u75b2\u52b4\u3001\u5026\u6020\u611f\u3001\u4f53\u91cd\u6e1b\u5c11\u3001\u982d\u75db\u3002<\/td>\n<td>\u533b\u5e2b\u306e\u8a31\u53ef\u304c\u51fa\u305f\u5834\u5408\u306f\u3001\u4f11\u606f\u671f\u9593\u3092\u8a2d\u3051\u3001\u8efd\u3044\u8eab\u4f53\u6d3b\u52d5\u306b\u53d6\u308a\u7d44\u3093\u3067\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3 data-path-to-node=\"35\">\u91cd\u7be4\u306a\u526f\u4f5c\u7528\uff08\u7dca\u6025\u533b\u7642\u304c\u5fc5\u8981\uff09<\/h3>\n<ul data-path-to-node=\"36\">\n<li>\n<div>\u91cd\u5ea6\u809d\u969c\u5bb3\uff08Boxed Warning\uff09\uff1a\u30d1\u30be\u30d1\u30cb\u30d6\u306f\u91cd\u5ea6\u306e\u3001\u81f4\u547d\u7684\u306a\u809d\u969c\u5bb3\u3092\u5f15\u304d\u8d77\u3053\u3059\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/div>\n<ul data-path-to-node=\"36,0,1\">\n<li>\n<div>\u75c7\u72b6\uff1a\u76ae\u819a\u3084\u773c\u306e\u9ec4\u75b8\u3001\u6fc3\u3044\u8336\u8272\u307e\u305f\u306f\u8336\u8272\u306e\u5c3f\u3001\u53f3\u4e0a\u8179\u90e8\u306e\u75db\u307f\u3001\u5f37\u3044\u5410\u304d\u6c17\u3001\u7570\u5e38\u306a\u75b2\u52b4\u3002<\/div>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<div>QT\u5ef6\u9577\u3068\u5fc3\u81d3\u4e0d\u6574\u8108\uff1a\u5fc3\u81d3\u306e\u96fb\u6c17\u7684\u30bf\u30a4\u30df\u30f3\u30b0\u3092\u5909\u5316\u3055\u305b\u3001\u5fc3\u5ba4\u6027\u4e0d\u6574\u8108\u3092\u5f15\u304d\u8d77\u3053\u3059\u30ea\u30b9\u30af\u304c\u3042\u308a\u307e\u3059\u3002<\/div>\n<ul data-path-to-node=\"36,1,1\">\n<li>\n<div>\u75c7\u72b6\uff1a\u5fc3\u60b8\u3001\u80f8\u306e\u5727\u8feb\u611f\u3001\u3081\u307e\u3044\u3001\u7acb\u3061\u304f\u3089\u307f\u3001\u7a81\u767a\u7684\u306a\u5931\u795e\u3002<\/div>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<div>\u51fa\u8840\u30a4\u30d9\u30f3\u30c8\uff1a\u5185\u90e8\u307e\u305f\u306f\u7c98\u819c\u306e\u51fa\u8840\u30ea\u30b9\u30af\u304c\u5897\u52a0\u3057\u307e\u3059\u3002<\/div>\n<ul data-path-to-node=\"36,2,1\">\n<li>\n<div>\u75c7\u72b6\uff1a\u8840\u3092\u54b3\u304d\u51fa\u3059\u3001\u9ed2\u3044\u30bf\u30fc\u30eb\u4fbf\u3001\u9f3b\u51fa\u8840\u3001\u4e88\u671f\u3057\u306a\u3044\u3042\u3056\u3002<\/div>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<div>\u80c3\u8178\u7a7f\u5b54\u3068\u763b\u7ba1\uff1a\u80c3\u3084\u8178\u306e\u58c1\u306b\u7a00\u306b\u7a74\u3084\u63a5\u7d9a\u304c\u3067\u304d\u308b\u3002<\/div>\n<ul data-path-to-node=\"36,3,1\">\n<li>\n<div>\u75c7\u72b6\uff1a\u6fc0\u3057\u3044\u8179\u75db\u306b\u52a0\u3048\u3066\u767a\u71b1\u3068\u5bd2\u6c17\u3002<\/div>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<div>\u52d5\u8108\u30fb\u9759\u8108\u8840\u6838\uff1a\u8840\u6813\uff08\u6df1\u90e8\u9759\u8108\u8840\u6813\u3001\u80ba\u585e\u6813\u3001\u5fc3\u7b4b\u6897\u585e\u3001\u8133\u5352\u4e2d\uff09\u306e\u30ea\u30b9\u30af\u3002<\/div>\n<ul data-path-to-node=\"36,4,1\">\n<li>\n<div>\u75c7\u72b6\uff1a\u7247\u5074\u306e\u811a\u306e\u75db\u307f\u3084\u816b\u308c\u3001\u92ed\u3044\u80f8\u306e\u75db\u307f\u3001\u7a81\u767a\u7684\u306a\u547c\u5438\u56f0\u96e3\u3001\u9854\u306e\u8131\u529b\u3084\u5f31\u3055\u3002<\/div>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h2 data-path-to-node=\"38\">\u6ce8\u610f\u4e8b\u9805\u3068\u5fc5\u9808\u306e\u5b89\u5168\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u30d7\u30ed\u30c8\u30b3\u30eb<\/h2>\n<div>\u5b89\u5168\u6027\u3092\u78ba\u4fdd\u3059\u308b\u305f\u3081\u3001\u533b\u7642\u30c1\u30fc\u30e0\u306f\u5b9a\u671f\u7684\u306a\u691c\u67fb\u3068\u8eab\u4f53\u8a55\u4fa1\u3092\u5fc5\u8981\u3068\u3057\u307e\u3059\u3002<\/div>\n<table data-path-to-node=\"40\">\n<thead>\n<tr>\n<td>\u691c\u67fb\u9805\u76ee<\/td>\n<td>\u63a8\u5968\u983b\u5ea6<\/td>\n<td>\u81e8\u5e8a\u7684\u6839\u62e0<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u809d\u6a5f\u80fd\u691c\u67fb\uff08ALT\u3001AST\u3001\u30d3\u30ea\u30eb\u30d3\u30f3\uff09<\/td>\n<td>\u521d\u56de\u3001\u6700\u521d\u306e9\u9031\u9593\u306f2\u9031\u9593\u3054\u3068\u3001\u305d\u306e\u5f8c\u306f\u67081\u56de<\/td>\n<td>\u91cd\u5ea6\u306e\u5316\u5b66\u6027\u809d\u708e\u3084\u809d\u4e0d\u5168\u3092\u9632\u3050\u305f\u3081\u306b\u3001\u65e9\u671f\u306b\u8840\u6e05\u30c8\u30e9\u30f3\u30b9\u30a2\u30df\u30ca\u30fc\u30bc\u306e\u4e0a\u6607\u3092\u691c\u51fa\u3057\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr>\n<td>\u8840\u5727\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0<\/td>\n<td>\u521d\u56de\u3001\u6700\u521d\u306e6\u9031\u9593\u306f\u90311\u56de\u3001\u305d\u306e\u5f8c\u306f\u8a3a\u7642\u3054\u3068\u306b<\/td>\n<td>\u9ad8\u8840\u5727\u304c\u5fc5\u8981\u306b\u5fdc\u3058\u3066\u964d\u5727\u85ac\u3067\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3055\u308c\u3066\u3044\u308b\u3053\u3068\u3092\u78ba\u8a8d\u3057\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr>\n<td>\u7532\u72b6\u817a\u6a5f\u80fd\uff08TSH \/ \u904a\u96e2T4\uff09<\/td>\n<td>\u521d\u56de\u3001\u305d\u306e\u5f8c4\uff5e6\u9031\u9593\u3054\u3068<\/td>\n<td>\u85ac\u5264\u8a98\u767a\u6027\u7532\u72b6\u817a\u6a5f\u80fd\u4f4e\u4e0b\u75c7\u3092\u78ba\u8a8d\u3057\u3001\u75b2\u52b4\u3084\u4f53\u91cd\u5909\u5316\u306b\u5bc4\u4e0e\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr>\n<td>\u5fc3\u96fb\u56f3\uff08ECG\uff09\u3068\u8840\u6e05\u96fb\u89e3\u8cea\uff08K\u207a\u3001Mg\u00b2\u207a\u3001Ca\u00b2\u207a\uff09<\/td>\n<td>\u521d\u56de\u3068\u5468\u671f\u7684\u306b\u5b9f\u65bd<\/td>\n<td>QTc\u5ef6\u9577\u3068\u96fb\u89e3\u8cea\u30d0\u30e9\u30f3\u30b9\u3092\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u3057\u307e\u3059\u3002<\/td>\n<\/tr>\n<tr>\n<td>\u5c3f\u691c\u67fb\uff08\u86cb\u767d\u5c3f\uff09<\/td>\n<td>\u57fa\u6e96\u5024\u304a\u3088\u3073\u5468\u671f\u7684\u8a55\u4fa1<\/td>\n<td>\u814e\u8840\u7ba1\u5909\u5316\u306b\u3088\u308b\u86cb\u767d\u6f0f\u51fa\u306e\u691c\u51fa<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3 data-path-to-node=\"41\">\u624b\u8853\u304a\u3088\u3073\u50b7\u306e\u6cbb\u7652\u306b\u95a2\u3059\u308b\u8b66\u544a<\/h3>\n<ul data-path-to-node=\"42\">\n<li>\n<div>\u969c\u5bb3\u306e\u3042\u308b\u50b7\u306e\u6cbb\u7652\uff1aPazolong\u306f\u65b0\u3057\u3044\u8840\u7ba1\u306e\u5f62\u6210\u3092\u963b\u5bb3\u3059\u308b\u305f\u3081\u3001\u50b7\u306e\u4fee\u5fa9\u3092\u8457\u3057\u304f\u59a8\u3052\u307e\u3059\u3002\u624b\u8853\u3092\u4e88\u5b9a\u3057\u3066\u3044\u308b\u5834\u5408\u306f\u3001\u5c11\u306a\u304f\u3068\u30827\u65e5\u524d\u306bPazolong\u306e\u670d\u7528\u3092\u4e2d\u6b62\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u624b\u8853\u5f8c\u306f\u5c11\u306a\u304f\u3068\u30822\u9031\u9593\u3001\u50b7\u304c\u5b8c\u5168\u306b\u7652\u5408\u3059\u308b\u307e\u3067Pazolong\u306e\u6295\u4e0e\u3092\u518d\u958b\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002<\/div>\n<\/li>\n<\/ul>\n<h2 data-path-to-node=\"44\">\u85ac\u7269\u76f8\u4e92\u4f5c\u7528\u304a\u3088\u3073\u7279\u5225\u96c6\u56e3\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3<\/h2>\n<div>Pazopanib\u306f\u4e3b\u306bCYP3A4\u9175\u7d20\u306b\u3088\u3063\u3066\u809d\u81d3\u3067\u4ee3\u8b1d\u3055\u308c\u3001\u9069\u5207\u306a\u6eb6\u89e3\u306b\u306f\u9178\u6027\u306e\u80c3\u74b0\u5883\u304c\u5fc5\u8981\u3067\u3059\u3002<\/div>\n<h3 data-path-to-node=\"46\">\u4e3b\u8981\u306a\u76f8\u4e92\u4f5c\u7528<\/h3>\n<ul data-path-to-node=\"47\">\n<li>\n<div>\u5f37\u3044CYP3A4\u963b\u5bb3\u85ac\uff08\u4f8b\uff1a\u30b1\u30c8\u30b3\u30ca\u30be\u30fc\u30eb\u3001\u30af\u30e9\u30ea\u30b9\u30ed\u30de\u30a4\u30b7\u30f3\uff09\uff1aPazopanib\u306e\u4ee3\u8b1d\u3092\u9045\u3089\u305b\u3001\u85ac\u7269\u6fc3\u5ea6\u304c\u4e0a\u6607\u3057\u3001\u6bd2\u6027\u304c\u5897\u52a0\u3057\u307e\u3059\u3002\u4f75\u7528\u3092\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002<\/div>\n<\/li>\n<li>\n<div>\u5f37\u3044CYP3A4\u8a98\u5c0e\u85ac\uff08\u4f8b\uff1a\u30ea\u30d5\u30a1\u30f3\u30d4\u30b7\u30f3\u3001\u30d5\u30a7\u30cb\u30c8\u30a4\u30f3\u3001\u30ab\u30d0\u30eb\u30de\u30bc\u30d4\u30f3\u3001\u30bb\u30f3\u30c8\u30fb\u30b8\u30e7\u30f3\u306e\u30ef\u30fc\u30c8\uff09\uff1aPazopanib\u306e\u4ee3\u8b1d\u3092\u4fc3\u9032\u3057\u3001\u85ac\u7269\u6fc3\u5ea6\u304c\u4f4e\u4e0b\u3057\u3066\u6297\u764c\u52b9\u679c\u304c\u6e1b\u5c11\u3057\u307e\u3059\u3002\u4f75\u7528\u3092\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002<\/div>\n<\/li>\n<li>\n<div>\u80c3\u9178\u5206\u6ccc\u963b\u5bb3\u85ac\uff08PPI\u304a\u3088\u3073H2\u30d6\u30ed\u30c3\u30ab\u30fc\uff09\uff1a\u30aa\u30e1\u30d7\u30e9\u30be\u30fc\u30eb\u3001\u30d1\u30f3\u30bf\u30be\u30fc\u30eb\u3001\u30d5\u30a1\u30e2\u30c1\u30b8\u30f3\u306a\u3069\u306e\u85ac\u306f\u80c3\u9178\u3092\u6e1b\u5c11\u3055\u305b\u3001Pazolong\u306e\u5438\u53ce\u3092\u8457\u3057\u304f\u4f4e\u4e0b\u3055\u305b\u307e\u3059\u3002<\/div>\n<ul data-path-to-node=\"47,2,1\">\n<li>\n<div>\u7ba1\u7406\u65b9\u6cd5\uff1aPPI\u304a\u3088\u3073H2\u30d6\u30ed\u30c3\u30ab\u30fc\u306e\u4f7f\u7528\u3092\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002\u80c3\u9178\u306e\u7de9\u548c\u304c\u5fc5\u8981\u306a\u5834\u5408\u306f\u3001Pazolong\u306e\u6295\u4e0e\u524d\u5f8c2\u6642\u9593\u4ee5\u4e0a\u9593\u9694\u3092\u7a7a\u3051\u3066\u77ed\u6642\u9593\u4f5c\u7528\u578b\u306e\u5236\u9178\u5264\u3092\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002<\/div>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<div>\u30b0\u30ec\u30fc\u30d7\u30d5\u30eb\u30fc\u30c4\u304a\u3088\u3073\u30bb\u30d3\u30ea\u30a2\u6a59\uff1aCYP3A4\u3092\u963b\u5bb3\u3057\u3001\u85ac\u7269\u6fc3\u5ea6\u304c\u6bd2\u6027\u30ec\u30d9\u30eb\u306b\u4e0a\u6607\u3059\u308b\u305f\u3081\u3001\u5b8c\u5168\u306b\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002<\/div>\n<\/li>\n<\/ul>\n<h3 data-path-to-node=\"48\">\u7279\u5225\u96c6\u56e3\u306e\u5b89\u5168\u6027\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3<\/h3>\n<ul data-path-to-node=\"49\">\n<li>\n<div>\u598a\u5a20\uff08\u53b3\u5bc6\u306b\u7981\u5fcc\uff09\uff1aPazolong\u306f\u80ce\u5150\u306b\u6709\u5bb3\u3067\u3042\u308a\u3001\u598a\u5a20\u640d\u5931\u3092\u5f15\u304d\u8d77\u3053\u3059\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u598a\u5a20\u53ef\u80fd\u306a\u5973\u6027\u306f\u6cbb\u7642\u958b\u59cb\u524d\u306b\u598a\u5a20\u691c\u67fb\u3092\u9670\u6027\u3067\u3042\u308b\u3053\u3068\u3092\u78ba\u8a8d\u3057\u3001\u6cbb\u7642\u4e2d\u304a\u3088\u3073\u6700\u7d42\u6295\u4e0e\u5f8c2\u9031\u9593\u306f\u78ba\u5b9f\u306a\u907f\u598a\u6cd5\u3092\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u7537\u6027\u60a3\u8005\u3067\u598a\u5a20\u53ef\u80fd\u306a\u5973\u6027\u30d1\u30fc\u30c8\u30ca\u30fc\u304c\u3044\u308b\u5834\u5408\u306f\u3001\u6cbb\u7642\u4e2d\u304a\u3088\u3073\u6700\u7d42\u6295\u4e0e\u5f8c2\u9031\u9593\u306f\u30b3\u30f3\u30c9\u30fc\u30e0\u3092\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002<\/div>\n<\/li>\n<li>\n<div>\u6388\u4e73\uff1a\u6cbb\u7642\u4e2d\u304a\u3088\u3073\u6700\u7d42\u6295\u4e0e\u5f8c2\u9031\u9593\u306f\u6388\u4e73\u3092\u7981\u5fcc\u3068\u3057\u307e\u3059\u3002<\/div>\n<\/li>\n<li>\n<div>\u5c0f\u5150\u4f7f\u7528\uff1a18\u6b73\u672a\u6e80\u306e\u60a3\u8005\u306b\u304a\u3051\u308b\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027\u306f\u78ba\u7acb\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002<\/div>\n<\/li>\n<\/ul>\n<h2 data-path-to-node=\"51\">\u4fdd\u7ba1\u3001\u53d6\u6271\u3044\u3001\u54c1\u8cea\u7ba1\u7406<\/h2>\n<ul data-path-to-node=\"52\">\n<li>\n<div>\u4fdd\u7ba1\u6761\u4ef6\uff1aPazolong 200mg \u30bf\u30d6\u30ec\u30c3\u30c8\u306f\u300120\u00b0C\uff5e25\u00b0C\uff0868\u00b0F\uff5e77\u00b0F\uff09\u306e\u5ba4\u6e29\u3067\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u5bb9\u5668\u306f\u5bc6\u9589\u3057\u3001\u76f4\u5c04\u5149\u3001\u71b1\u3001\u6e7f\u6c17\u304b\u3089\u9060\u3056\u3051\u305f\u4e7e\u71e5\u3057\u305f\u5834\u6240\u306b\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002<\/div>\n<\/li>\n<li>\n<div>\u5b89\u5168\u306a\u53d6\u6271\u3044\uff1a\u5b50\u4f9b\u3068\u30da\u30c3\u30c8\u306e\u624b\u306e\u5c4a\u304b\u306a\u3044\u5834\u6240\u306b\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u53d6\u6271\u8005\u306f\u30bf\u30d6\u30ec\u30c3\u30c8\u3092\u53d6\u308a\u6271\u3063\u305f\u5f8c\u3001\u5341\u5206\u306b\u624b\u3092\u6d17\u3063\u3066\u304f\u3060\u3055\u3044\u3002<\/div>\n<\/li>\n<li>\n<div>\u88fd\u9020\u57fa\u6e96\uff1aMSN Laboratories\u304c\u88fd\u9020\u3057\u305fPazolong\u306f\u3001WHO-GMP\u304a\u3088\u3073ISO\u54c1\u8cea\u57fa\u6e96\u3092\u6e80\u305f\u3059\u65bd\u8a2d\u3067\u751f\u7523\u3055\u308c\u3001\u5316\u5b66\u7d14\u5ea6\u3001\u5747\u4e00\u306a\u6eb6\u89e3\u3001\u4e00\u8cab\u3057\u305f\u6295\u4e0e\u91cf\u3092\u78ba\u4fdd\u3057\u3066\u3044\u307e\u3059\u3002<\/div>\n<\/li>\n<\/ul>\n<h2 data-path-to-node=\"54\">\u3088\u304f\u3042\u308b\u8cea\u554f\uff08FAQ\uff09<\/h2>\n<h4 data-path-to-node=\"55\">Q1\uff1a\u306a\u305c\u533b\u5e2b\u304c400mg\u306e\u5f37\u5ea6\u3067\u306f\u306a\u304f200mg\u306e\u30bf\u30d6\u30ec\u30c3\u30c8\u3092\u51e6\u65b9\u3057\u305f\u306e\u3067\u3059\u304b\uff1f<\/h4>\n<div>200mg\u306e\u5f37\u5ea6\u306f\u6295\u4e0e\u306e\u67d4\u8edf\u6027\u3092\u8a31\u53ef\u3057\u307e\u3059\u3002\u6a19\u6e96\u7684\u306a800mg\u306e1\u65e5\u91cf\u30924\u9320\u306e200mg\u30bf\u30d6\u30ec\u30c3\u30c8\u3067\u9054\u6210\u3059\u308b\u304b\u3001600mg\u3001400mg\u3001\u307e\u305f\u306f200mg\u306e1\u65e5\u91cf\u306b\u6bb5\u968e\u7684\u306b\u6e1b\u3089\u3059\u3053\u3068\u304c\u3067\u304d\u3001\u809d\u6a5f\u80fd\u3084\u500b\u3005\u306e\u8010\u6027\u306b\u5fdc\u3058\u3066\u816b\u760d\u79d1\u533b\u304c\u6295\u4e0e\u91cf\u3092\u30ab\u30b9\u30bf\u30de\u30a4\u30ba\u3067\u304d\u308b\u3088\u3046\u306b\u3057\u307e\u3059\u3002<\/div>\n<h4 data-path-to-node=\"57\">Q2\uff1aPazolong\u306e\u670d\u7528\u4e2d\u306b\u9aea\u304c\u8584\u304f\u306a\u308b\u307e\u305f\u306f\u767d\u304f\u306a\u308b\u306e\u306f\u306a\u305c\u3067\u3059\u304b\uff1f<\/h4>\n<div>\u9aea\u3084\u76ae\u819a\u306e\u8272\u7d20\u6c88\u7740\u306e\u6e1b\u5c11\uff08\u8131\u8272\u7d20\uff09\u306f\u3001Pazolong\u306e\u4e00\u822c\u7684\u3067\u7121\u5bb3\u306a\u526f\u4f5c\u7528\u3067\u3059\u3002\u3053\u308c\u306f\u3001\u30e1\u30e9\u30cb\u30f3\u8272\u7d20\u306e\u751f\u6210\u306b\u95a2\u4e0e\u3059\u308b\u53d7\u5bb9\u4f53\u7d4c\u8def\uff08\u4f8b\uff1ac-KIT\uff09\u3092\u963b\u5bb3\u3059\u308b\u305f\u3081\u3067\u3059\u3002\u85ac\u306e\u670d\u7528\u3092\u505c\u6b62\u3059\u308c\u3070\u3001\u901a\u5e38\u306f\u9aea\u306e\u8272\u306f\u5143\u306b\u623b\u308a\u307e\u3059\u3002<\/div>\n<h4 data-path-to-node=\"59\">Q3\uff1a\u671d\u306e\u7d05\u8336\u3001\u30b3\u30fc\u30d2\u30fc\u3001\u307e\u305f\u306f\u725b\u4e73\u3068\u4e00\u7dd2\u306bPazolong\u3092\u670d\u7528\u3057\u3066\u3082\u3044\u3044\u3067\u3059\u304b\uff1f<\/h4>\n<div>\u3044\u3044\u3048\u3002Pazolong\u306f\u7a7a\u8179\u6642\u306b\u6c34\u3060\u3051\u3067\u670d\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u98df\u4e8b\u3084\u30b9\u30ca\u30c3\u30af\u306e\u524d\u5f8c1\u6642\u9593\u4ee5\u4e0a\u3001\u307e\u305f\u306f\u6700\u5f8c\u306e\u98df\u4e8b\u5f8c2\u6642\u9593\u4ee5\u4e0a\u7d4c\u904e\u3059\u308b\u307e\u3067\u670d\u7528\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002<\/div>\n<h4 data-path-to-node=\"61\">Q4\uff1aPazolong\u306e\u670d\u7528\u958b\u59cb\u5f8c\u306b\u8840\u5727\u304c\u4e0a\u6607\u3057\u305f\u5834\u5408\u3001\u3069\u3046\u3059\u308c\u3070\u3044\u3044\u3067\u3059\u304b\uff1f<\/h4>\n<div>\u9ad8\u8840\u5727\u306f\u6297\u8840\u7ba1\u65b0\u751f\u7642\u6cd5\u306e\u65e2\u77e5\u306e\u3001\u7ba1\u7406\u53ef\u80fd\u306a\u526f\u4f5c\u7528\u3067\u3059\u3002\u81ea\u5b85\u3067\u8840\u5727\u3092\u9031\u306b1\u56de\u6e2c\u5b9a\u3057\u3001\u8a18\u9332\u3092\u533b\u7642\u30c1\u30fc\u30e0\u306b\u5171\u6709\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u307b\u3068\u3093\u3069\u306e\u5834\u5408\u3001\u816b\u760d\u79d1\u533b\u306f\u6a19\u6e96\u7684\u306a\u7d4c\u53e3\u8840\u5727\u964d\u4e0b\u85ac\u3092\u51e6\u65b9\u3057\u3066\u3001\u85ac\u7269\u7642\u6cd5\u3092\u4e2d\u6b62\u305b\u305a\u306b\u8840\u5727\u3092\u5b89\u5168\u7bc4\u56f2\u306b\u4fdd\u3064\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002<\/div>\n<h3 data-path-to-node=\"64,0\">\u533b\u7642\u4e0a\u306e\u514d\u8cac\u4e8b\u9805<\/h3>\n<div>\u3053\u306e\u81e8\u5e8a\u30ac\u30a4\u30c9\u306f\u6559\u80b2\u7684\u304a\u3088\u3073\u60c5\u5831\u63d0\u4f9b\u76ee\u7684\u306e\u307f\u3092\u76ee\u7684\u3068\u3057\u3066\u304a\u308a\u3001\u5c02\u9580\u7684\u306a\u533b\u7642\u30a2\u30c9\u30d0\u30a4\u30b9\u3001\u8a3a\u65ad\u3001\u307e\u305f\u306f\u6cbb\u7642\u3092\u4ee3\u66ff\u3059\u308b\u3082\u306e\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002\u304c\u3093\u6cbb\u7642\u3084\u51e6\u65b9\u85ac\u306e\u958b\u59cb\u3001\u5909\u66f4\u3001\u307e\u305f\u306f\u4e2d\u6b62\u306e\u524d\u306b\u3001\u5fc5\u305a\u8cc7\u683c\u306e\u3042\u308b\u816b\u760d\u79d1\u533b\u307e\u305f\u306f\u533b\u7642\u5c02\u9580\u5bb6\u306b\u3054\u76f8\u8ac7\u304f\u3060\u3055\u3044\u3002<\/div>\n<h2 data-path-to-node=\"66\">\u53c2\u8003\u6587\u732e<\/h2>\n<ol start=\"1\" data-path-to-node=\"67\">\n<li>\n<div>\u56fd\u7acb\u751f\u7269\u6280\u8853\u60c5\u5831\u30bb\u30f3\u30bf\u30fc\uff08NCBI\uff09\uff1a<\/div>\n<ul data-path-to-node=\"67,0,1\">\n<li>\n<div>StatPearls\u30ec\u30d3\u30e5\u30fc\uff1aPazopanib\u306e\u85ac\u7406\u5b66\u3001\u9069\u5fdc\u3001\u81e8\u5e8a\u5fdc\u7528\u3002 <a href=\"https:\/\/www.google.com\/search?q=https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557622\/\" target=\"_blank\" rel=\"noopener nofollow\" data-hveid=\"0\" data-ved=\"0CAAQ_4QMahgKEwiJktDwkqCWAxUAAAAAHQAAAAAQ4wM\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557622\/<\/a><\/div>\n<\/li>\n<li>\n<div>PMC\u81e8\u5e8a\u7814\u7a76\uff1aPazopanib\u306e\u9ad8\u5ea6\u814e\u7d30\u80de\u764c\u304a\u3088\u3073\u8edf\u90e8\u8089\u816b\u306e\u7ba1\u7406\u3002 <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3234149\/\" target=\"_blank\" rel=\"noopener nofollow\" data-hveid=\"0\" data-ved=\"0CAAQ_4QMahgKEwiJktDwkqCWAxUAAAAAHQAAAAAQ5AM\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3234149\/<\/a><\/div>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<div>\u7c73\u56fd\u98df\u54c1\u533b\u85ac\u54c1\u5c40\uff08FDA\uff09\uff1a<\/div>\n<ul data-path-to-node=\"67,1,1\">\n<li>\n<div>VOTRIENT\uff08pazopanib\uff09\u51e6\u65b9\u60c5\u5831\u304a\u3088\u3073\u30d6\u30e9\u30c3\u30af\u30dc\u30c3\u30af\u30b9\u8b66\u544a\u3002 <a href=\"https:\/\/www.google.com\/search?q=https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022465s032lbl.pdf\" target=\"_blank\" rel=\"noopener nofollow\" data-hveid=\"0\" data-ved=\"0CAAQ_4QMahgKEwiJktDwkqCWAxUAAAAAHQAAAAAQ5QM\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022465s032lbl.pdf<\/a><\/div>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<div>MedlinePlus Drug Information (US National Library of Medicine):<\/div>\n<ul data-path-to-node=\"67,2,1\">\n<li>\n<div>Pazopanib Monograph &amp; Patient Safety Guidelines. <a href=\"https:\/\/medlineplus.gov\/druginfo\/meds\/a610013.html\" target=\"_blank\" rel=\"noopener nofollow\" data-hveid=\"0\" data-ved=\"0CAAQ_4QMahgKEwiJktDwkqCWAxUAAAAAHQAAAAAQ5gM\">https:\/\/medlineplus.gov\/druginfo\/meds\/a610013.html<\/a><\/div>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<div>Electronic Medicines Compendium (EMC):<\/div>\n<ul data-path-to-node=\"67,3,1\">\n<li>\n<div>Pazopanib Film-Coated Tablets Summary of Product Characteristics (SmPC). <a href=\"https:\/\/www.google.com\/search?q=https:\/\/www.medicines.org.uk\/emc\/product\/6797\/smpc\" target=\"_blank\" rel=\"noopener nofollow\" data-hveid=\"0\" data-ved=\"0CAAQ_4QMahgKEwiJktDwkqCWAxUAAAAAHQAAAAAQ5wM\">https:\/\/www.medicines.org.uk\/emc\/product\/6797\/smpc<\/a><\/div>\n<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<div><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Comprehensive Patient &#038; Clinician Guide to Pazolong 200mg Tablet (Pazopanib Hydrochloride) Pazolong 200mg [&hellip;]<\/p>\n","protected":false},"featured_media":131677,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5817,15843],"product_tag":[22664,12240,15912,15911],"igm_manufacturer":[],"class_list":["post-71617","product","type-product","status-publish","has-post-thumbnail","product_cat-chronic-conditions","product_cat-gastroenterology","product_tag-pazolong","product_tag-pazopanib","product_tag-strip","product_tag-tablet","pa_brand-name-pazolong","pa_molecule-pazopanib","first","instock","sale","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/product\/71617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/comments?post=71617"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/media\/131677"}],"wp:attachment":[{"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/media?parent=71617"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/product_brand?post=71617"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/product_cat?post=71617"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/product_tag?post=71617"},{"taxonomy":"igm_manufacturer","embeddable":true,"href":"https:\/\/indogenmed.org\/ja\/wp-json\/wp\/v2\/igm_manufacturer?post=71617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}